In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro) ; volume:10 ; number:1 ; day:9 ; month:9 ; year:2024 ; pages:1-22 ; date:12.2024
Future Journal of Pharmaceutical Sciences ; 10, Heft 1 (9.9.2024), 1-22, 12.2024

Creator: Kishore, Merusomayajula V.
Rao, T. Siva
Kumari, G. N. D.

Contributor: SpringerLink (Online service)

DOI: 10.1186/s43094-024-00685-3

URN: urn:nbn:de:101:1-2411222110447.486460170770

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:31 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kishore, Merusomayajula V.
Rao, T. Siva
Kumari, G. N. D.
SpringerLink (Online service)

Other Objects (12)

Synthesis of HCV Protease Inhibitor MK-6325

Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Hochschulschrift

In silico screening of inhibitors and conformational analysis of HCV NS5B polymerase

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Lysosomotropic agents as HCV entry inhibitors

Hochschulschrift

Novel inhibitors for the protease Taspase1

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Hochschulschrift

Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir

Hochschulschrift

Crystal structure studies of natural protease inhibitors

Hochschulschrift

Peptidic and peptidomimetic inhibitors of dengue protease

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

Synthesis of HCV Protease Inhibitor MK-6325

Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Hochschulschrift

In silico screening of inhibitors and conformational analysis of HCV NS5B polymerase

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Lysosomotropic agents as HCV entry inhibitors

Hochschulschrift

Novel inhibitors for the protease Taspase1

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Hochschulschrift

Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir

Hochschulschrift

Crystal structure studies of natural protease inhibitors

Hochschulschrift

Peptidic and peptidomimetic inhibitors of dengue protease

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

Synthesis of HCV Protease Inhibitor MK-6325

Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

Hochschulschrift

In silico screening of inhibitors and conformational analysis of HCV NS5B polymerase

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Lysosomotropic agents as HCV entry inhibitors

Hochschulschrift

Novel inhibitors for the protease Taspase1

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Hochschulschrift

Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir

Hochschulschrift

Crystal structure studies of natural protease inhibitors

Hochschulschrift

Peptidic and peptidomimetic inhibitors of dengue protease

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Synthesis of HCV Protease Inhibitor MK-6325

Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

In silico screening of inhibitors and conformational analysis of HCV NS5B polymerase

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Lysosomotropic agents as HCV entry inhibitors

Novel inhibitors for the protease Taspase1

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir

Crystal structure studies of natural protease inhibitors

Peptidic and peptidomimetic inhibitors of dengue protease

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

Synthesis of HCV Protease Inhibitor MK-6325

Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

In silico screening of inhibitors and conformational analysis of HCV NS5B polymerase

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Lysosomotropic agents as HCV entry inhibitors

Novel inhibitors for the protease Taspase1

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir

Crystal structure studies of natural protease inhibitors

Peptidic and peptidomimetic inhibitors of dengue protease

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

Synthesis of HCV Protease Inhibitor MK-6325

Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

In silico screening of inhibitors and conformational analysis of HCV NS5B polymerase

Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors

Lysosomotropic agents as HCV entry inhibitors

Novel inhibitors for the protease Taspase1

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283

Pharmakokinetik der Protease-Inhibitoren Lopinavir und Ritonavir

Crystal structure studies of natural protease inhibitors

Peptidic and peptidomimetic inhibitors of dengue protease

Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences

Related objects

Reset password